They are responsible for investigating any safety concerns regarding the licensing of diethylstilbestrol (DES). Scottish Government officials meet regularly with the MHRA to discuss known medicine safety issues and to agree required actions.The most recent guidance published by the Department of Health, which also applies in Scotland, advises that daughters of individuals exposed to DES in utero are at an increased risk of clear cell cancer of the cervix and vagina but no other forms of cervical cancer and that local arrangements should be made for the follow up of individuals who are DES daughters and have the stigmata of DES exposure.